CN106632063B - Compound I and compound II based on phenanthroimidazole and its preparation method and application - Google Patents
Compound I and compound II based on phenanthroimidazole and its preparation method and application Download PDFInfo
- Publication number
- CN106632063B CN106632063B CN201510730596.5A CN201510730596A CN106632063B CN 106632063 B CN106632063 B CN 106632063B CN 201510730596 A CN201510730596 A CN 201510730596A CN 106632063 B CN106632063 B CN 106632063B
- Authority
- CN
- China
- Prior art keywords
- compound
- carboxylic acid
- preparation
- structures
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 title abstract 3
- GZPPANJXLZUWHT-UHFFFAOYSA-N 1h-naphtho[2,1-e]benzimidazole Chemical compound C1=CC2=CC=CC=C2C2=C1C(N=CN1)=C1C=C2 GZPPANJXLZUWHT-UHFFFAOYSA-N 0.000 title description 6
- 239000000523 sample Substances 0.000 claims abstract description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000001624 naphthyl group Chemical group 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 12
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 11
- 239000005695 Ammonium acetate Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 9
- JLZUZNKTTIRERF-UHFFFAOYSA-N tetraphenylethylene Chemical group C1=CC=CC=C1C(C=1C=CC=CC=1)=C(C=1C=CC=CC=1)C1=CC=CC=C1 JLZUZNKTTIRERF-UHFFFAOYSA-N 0.000 claims description 9
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 7
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- WGLQHUKCXBXUDV-UHFFFAOYSA-N 3-aminophthalic acid Chemical compound NC1=CC=CC(C(O)=O)=C1C(O)=O WGLQHUKCXBXUDV-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 229940113088 dimethylacetamide Drugs 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 abstract description 22
- -1 phenanthroimidazole carboxylic acid Chemical class 0.000 abstract description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 125000001424 substituent group Chemical group 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract description 2
- 238000006862 quantum yield reaction Methods 0.000 abstract description 2
- 239000000376 reactant Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- 125000003118 aryl group Chemical group 0.000 description 23
- 125000003545 alkoxy group Chemical group 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- 229960000583 acetic acid Drugs 0.000 description 15
- 125000003277 amino group Chemical group 0.000 description 13
- 239000007850 fluorescent dye Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 125000004076 pyridyl group Chemical group 0.000 description 12
- 125000002541 furyl group Chemical group 0.000 description 11
- 125000001041 indolyl group Chemical group 0.000 description 11
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 11
- 125000001544 thienyl group Chemical group 0.000 description 11
- 125000003944 tolyl group Chemical group 0.000 description 11
- 125000000217 alkyl group Chemical class 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 125000000168 pyrrolyl group Chemical group 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229940043376 ammonium acetate Drugs 0.000 description 9
- 235000019257 ammonium acetate Nutrition 0.000 description 9
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 150000003934 aromatic aldehydes Chemical class 0.000 description 6
- 150000004982 aromatic amines Chemical group 0.000 description 6
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 6
- SCOAVUHOIJMIBW-UHFFFAOYSA-N phenanthrene-1,2-dione Chemical class C1=CC=C2C(C=CC(C3=O)=O)=C3C=CC2=C1 SCOAVUHOIJMIBW-UHFFFAOYSA-N 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 description 5
- 125000002843 carboxylic acid group Chemical group 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002189 fluorescence spectrum Methods 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 description 1
- PIQBPEJQHQFBRT-UHFFFAOYSA-N 1h-imidazole;phenanthrene Chemical compound C1=CNC=N1.C1=CC=C2C3=CC=CC=C3C=CC2=C1 PIQBPEJQHQFBRT-UHFFFAOYSA-N 0.000 description 1
- WRQHNSKKYGHTLO-UHFFFAOYSA-N 1h-phenanthro[9,10-d]imidazole Chemical compound C12=CC=CC=C2C2=CC=CC=C2C2=C1NC=N2 WRQHNSKKYGHTLO-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- OXSANYRLJHSQEP-UHFFFAOYSA-N 4-aminophthalic acid Chemical compound NC1=CC=C(C(O)=O)C(C(O)=O)=C1 OXSANYRLJHSQEP-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1011—Condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明涉及化合物I和化合物II及其制备方法和应用,通过在Ar处引入不同的取代基结构,实现对上述化合物的发光颜色、效率的调节;有效的遏制化合物在固态下效率的损失,实现其水系条件下高的荧光量子产率;通过选择不同的氨基羧酸结构作为反应物,在N1苯环处引入不同的羧酸结构,并通过适当的方法制备各种羧酸衍生结构,以提高上述化合物结构的分子相容性、识别能力等。化合物I和化合物II作为一类新型的探针结构,菲并咪唑羧酸和羧酸衍生物能够自由的进出细胞,并对特定结构进行选择性识别与成像,使其在生物、医疗、健康和监测领域,具有极其广阔的应用前景。
The present invention relates to compound I and compound II and their preparation methods and applications. By introducing different substituent structures at Ar, the adjustment of the luminous color and efficiency of the above compounds can be realized; the loss of efficiency of the compounds in the solid state can be effectively curbed, and the realization of Its high fluorescence quantum yield under water system conditions; by selecting different aminocarboxylic acid structures as reactants, introducing different carboxylic acid structures at the N1 benzene ring, and preparing various carboxylic acid derivative structures by appropriate methods to improve The molecular compatibility and recognition ability of the above compound structure. Compound I and compound II are a new type of probe structure, phenanthroimidazole carboxylic acid and carboxylic acid derivatives can freely enter and exit cells, and selectively recognize and image specific structures, making them useful in biology, medicine, health and The field of monitoring has extremely broad application prospects.
Description
技术领域technical field
本发明涉及分析和检测技术领域,更具体地说,涉及化合物I和化合物II及其制备方法和应用。The present invention relates to the technical field of analysis and detection, more specifically, relates to compound I and compound II and their preparation methods and applications.
背景技术Background technique
随着国家经济的快速发展和人民生活水平的不断提高,个人身体健康的实时监测、疾病的预防和治疗逐渐成为人们更加关注的民生问题。相对于传统的体外化学检验的延迟性和放射线在线检测的危害性,荧光在线显像技术以其高效、绿色、实时性强的优势渐渐走入人们的视野,被广泛应用于细胞免疫学、微生物学、分子生物学、遗传学、神经生物学、病理学、肿瘤学、临床检验学、医学、植物学等方面的科研和民生等领域。With the rapid development of the national economy and the continuous improvement of people's living standards, real-time monitoring of personal health, disease prevention and treatment have gradually become people's livelihood issues that people pay more attention to. Compared with the delay of traditional in vitro chemical testing and the harmfulness of online radiation detection, fluorescence online imaging technology has gradually entered people's field of vision with its advantages of high efficiency, greenness and strong real-time performance, and has been widely used in cellular immunology, microbiology, etc. Science, molecular biology, genetics, neurobiology, pathology, oncology, clinical laboratory science, medicine, botany and other fields of scientific research and people's livelihood.
荧光显像技术的关键技术就是荧光物质作为标记探针(或染色剂)的选择。理想的探针分子通过物理或化学作用,特异性吸附在特定的细胞和组织上,在低能量光学辐照下实现二维或三维的成像,通过与荧光颜色、强度和分布情况来判断细胞或组织的健康情况。与普通的化学染色相比,荧光染色的灵敏度要高出100-1000倍,而且通过适当的功能修饰即可实现对活体的在线分析。The key technology of fluorescence imaging technology is the selection of fluorescent substances as labeled probes (or dyes). Ideal probe molecules are specifically adsorbed on specific cells and tissues through physical or chemical actions, and realize two-dimensional or three-dimensional imaging under low-energy optical irradiation, and judge cells or the health of the organization. Compared with ordinary chemical staining, the sensitivity of fluorescent staining is 100-1000 times higher, and online analysis of living organisms can be realized through appropriate functional modification.
通常,荧光探针结构有2-3部分组成,即发光基元、链接基元(可选)和识别基元。其中,发光基元主要负责在外界环境刺激(光、电或磁作用)实现高效率的发光,进而被外界信号检测设备检出变成可 视化信息;识别基元主要是对细胞或体内的靶向目标起到识别作用,以提高探针的定位能力;链接基元主要是将二者链接起来,使发光位置与被探测结构具有稳定的对应关系,保证检测过程的准确性。在实际应用中,为了简化荧光探针结构制备过程和降低成本,荧光探针的识别基元和发光核心也可由探针分子中的同一化学结构担任,但是这与化合物的发光机理和识别作用有很大关系,既不能相互干扰,又要实现快速响应和高度分辨,这将是荧光探针未来发展的主流方向。Usually, the structure of a fluorescent probe consists of 2-3 parts, namely a luminescence motif, a link motif (optional) and a recognition motif. Among them, the luminescent element is mainly responsible for achieving high-efficiency luminescence under external environmental stimuli (light, electricity, or magnetic action), and then detected by external signal detection equipment and turned into visual information; the recognition element is mainly for targeting cells or the body. The target plays the role of identification to improve the positioning ability of the probe; the link primitive is mainly to link the two, so that the light-emitting position and the structure to be detected have a stable corresponding relationship, ensuring the accuracy of the detection process. In practical applications, in order to simplify the preparation process of the fluorescent probe structure and reduce the cost, the recognition motif and the luminescent core of the fluorescent probe can also be served by the same chemical structure in the probe molecule, but this has something to do with the luminescent mechanism and recognition of the compound. There is a great relationship, neither mutual interference, but also fast response and high resolution, this will be the mainstream direction of future development of fluorescent probes.
菲并咪唑作为一类新型发光材料,具有较高的发光效率、优异的光热稳定性、相对平衡的载流子注入\传输能力,在发光材料领域展现了较大的应用潜力;同时,菲并咪唑也是一类抗癌型药物的母体结构,说明其具有一定的分子识别和定位能力。虽然上述两种优势的结合使菲并咪唑满足了一类理想的荧光探针构筑基元的要求,但是菲并咪唑这类高芳香性稠环的生物相容性较差,且识别定位能力较差,还无法作为荧光探针进行应用,需要引入其它基团对其性能进行调节。As a new type of luminescent material, phenanthrene imidazole has high luminous efficiency, excellent photothermal stability, relatively balanced carrier injection and transport capabilities, and has shown great application potential in the field of luminescent materials; at the same time, phenanthrene And imidazole is also the parent structure of a class of anticancer drugs, indicating that it has certain molecular recognition and localization capabilities. Although the combination of the above two advantages makes phenanthroimidazole meet the requirements of an ideal fluorescent probe building block, the biocompatibility of highly aromatic fused rings such as phenanthroimidazole is poor, and the ability to recognize and position is poor. Poor, it cannot be used as a fluorescent probe, and other groups need to be introduced to adjust its performance.
发明内容Contents of the invention
本发明的目的在于提供结构通式为式I和式II的化合物及其制备方法和应用,即化合物I和化合物II及其制备方法和应用,具体是提供一类基于菲并咪唑N1取代的羧酸及羧酸衍生物,解决了现有技术中的菲并咪唑类化合物尚无法实现作为荧光探针应用的问题。The object of the present invention is to provide the general structural formula as the compound of formula I and formula II and its preparation method and application, i.e. compound I and compound II and its preparation method and application, specifically to provide a class of carboxyl substituted based on phenanthroimidazole N1 The acid and carboxylic acid derivatives solve the problem that the phenanthroimidazole compounds in the prior art cannot be used as fluorescent probes.
本发明解决技术问题所采用的技术方案是:一种式I的化合物,具有如下结构通式:The technical solution adopted by the present invention to solve the technical problem is: a compound of formula I has the following structural formula:
其中,Ar表示芳香基团或其衍生结构,Ar选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、三苯基乙烯、四苯基乙烯及其相应的衍生结构中的一种;R选自羟基、卤素、烷氧基、芳香酚基团、胺基及芳香胺基及其相应的衍生物中的一种;G1和G2分别表示菲环上任意位置的任意取代基团。Among them, Ar represents an aromatic group or its derivative structure, and Ar is selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carbazole R group, anilino group, triphenylethylene, tetraphenylethylene and their corresponding derivative structures; R is selected from hydroxyl, halogen, alkoxy group, aromatic phenol group, amino group and aromatic amino group and its corresponding One of the derivatives; G1 and G2 respectively represent any substituent group at any position on the phenanthrene ring.
在本发明式I的化合物中,G1和G2分别表示氢。In the compounds of formula I according to the invention, G1 and G2 each represent hydrogen.
本发明还提供了上述式I的化合物的制备方法,包括如下步骤:The present invention also provides a preparation method for the compound of the above formula I, comprising the steps of:
S1、将芳香醛衍生物菲醌衍生物乙酸铵和氨基苯甲酸在有机溶剂中加热至80℃-180℃,反应1-24小时后冷却至室温,过滤,得到 S1, the aromatic aldehyde derivative Phenanthrenequinone Derivatives Ammonium acetate and aminobenzoic acid Heating to 80°C-180°C in an organic solvent, cooling to room temperature after reacting for 1-24 hours, filtering to obtain
其中,Ar选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、三苯基乙烯、 四苯基乙烯及其相应的衍生结构中的一种;G1和G2各自分别表示菲环上任意位置的任意取代基团。Wherein, Ar is selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carbazolyl, anilino, triphenylethylene, One of tetraphenylethylene and its corresponding derivative structures; G1 and G2 each represent any substituent group at any position on the phenanthrene ring.
在步骤S1后还包括步骤S2:Step S2 is also included after step S1:
S2、将S1步骤中制备得到的中的羟基分别进行相对应的取代反应得到由R取代的式I的化合物,其中R选自卤素、烷氧基、芳香酚基团、胺基及芳香胺基及其相应的衍生物中的一种。S2, the prepared in the step S1 The hydroxyl groups in the group are subjected to corresponding substitution reactions to obtain the compound of formula I substituted by R, wherein R is selected from one of halogen, alkoxy group, aromatic phenol group, amino group, aromatic amino group and their corresponding derivatives. kind.
在本发明式I的化合物的制备方法中,在步骤S1中,优选加热至100℃-120℃;优选反应2-4小时后冷却至室温;所述有机溶剂优选选自乙酸、四氢呋喃、甲苯、苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺和N-甲基吡咯烷酮中的任意一种或多种,最优选乙酸以及乙酸与其它溶剂的混合体系,即乙酸与四氢呋喃、甲苯、苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺和N-甲基吡咯烷酮中的任意一种或多种的混合体系。In the preparation method of the compound of formula I of the present invention, in step S1, preferably heating to 100°C-120°C; preferably cooling to room temperature after reacting for 2-4 hours; the organic solvent is preferably selected from acetic acid, tetrahydrofuran, toluene, Any one or more of benzene, N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone, most preferably acetic acid and the mixed system of acetic acid and other solvents, namely acetic acid Mixed system with any one or more of tetrahydrofuran, toluene, benzene, N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone.
进一步地,在步骤S1与步骤S2之间还可包括步骤S3:对S1步骤得到的进一步提纯,可采用重结晶和柱层析法,其中重结晶溶剂优选四氢呋喃、乙醇、甲苯或N,N-二甲基甲酰胺,更优选N,N-二甲基甲酰胺。Further, step S3 may also be included between step S1 and step S2: for the obtained For further purification, recrystallization and column chromatography can be used, wherein the recrystallization solvent is preferably tetrahydrofuran, ethanol, toluene or N,N-dimethylformamide, more preferably N,N-dimethylformamide.
本发明还提供另外一种式II的化合物,具有如下结构通式:The present invention also provides another compound of formula II, which has the following general structural formula:
其中,Ar表示芳香基团或其衍生结构,Ar选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、三苯基乙烯、四苯基乙烯及其相应的衍生结构中的一种;R和R1各自分别选自羟基、卤素、烷氧基、芳香酚基团、胺基及芳香胺基及其相应的衍生物中的一种;G1和G2各自分别表示菲环上任意位置的任意取代基团。Among them, Ar represents an aromatic group or its derivative structure, and Ar is selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carbazole One of base, anilino, triphenylethylene, tetraphenylethylene and their corresponding derivative structures; R and R1 are each selected from hydroxyl, halogen, alkoxy, aromatic phenol group, amino and aromatic One of the amine group and its corresponding derivatives; G1 and G2 each represent any substituent group at any position on the phenanthrene ring.
在本发明的式II的化合物中,G1和G2分别表示氢。In the compounds of formula II according to the invention, G1 and G2 each represent hydrogen.
本发明还提供了上述式II的化合物的制备方法,包括如下步骤:Sa、将芳香醛衍生物菲醌衍生物乙酸铵和氨基苯二甲酸在有机溶剂中加热至80℃-180℃,反应1-24小时后冷却至室温,过滤,得到 The present invention also provides a preparation method for the compound of the above formula II, comprising the following steps: Sa, aromatic aldehyde derivative Phenanthrenequinone Derivatives Ammonium acetate and aminophthalic acid Heating to 80°C-180°C in an organic solvent, cooling to room temperature after reacting for 1-24 hours, filtering to obtain
其中,Ar选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡 啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、三苯基乙烯、四苯基乙烯及其相应的衍生结构中的一种;G1和G2各自分别表示菲环上任意位置的任意取代基团。Wherein, Ar is selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carbazolyl, anilino, triphenylethylene, One of tetraphenylethylene and its corresponding derivative structures; G1 and G2 each represent any substituent group at any position on the phenanthrene ring.
在式II的化合物的制备方法中,在步骤Sa后还包括步骤Sb:In the preparation method of the compound of formula II, step Sb is also included after step Sa:
Sb、将Sa步骤中制备得到的中的两个羟基各自分别进行相对应的取代反应得到分别由R和R1取代的式II的化合物,其中R和R1各自分别选自卤素、烷氧基、芳香酚基团、胺基及芳香胺基及其相应的衍生物中的一种。Sb, prepared in the Sa step The two hydroxyl groups in each undergo corresponding substitution reactions respectively to obtain the compound of formula II substituted by R and R 1 respectively, wherein R and R 1 are each selected from halogen, alkoxyl group, aromatic phenol group, amino group and One of aromatic amine groups and their corresponding derivatives.
在本发明式II的化合物的制备方法中,在步骤Sa中,优选加热至100℃-120℃;优选反应2-4小时后冷却至室温;所述有机溶剂优选选自乙酸、四氢呋喃、甲苯、苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺和N-甲基吡咯烷酮中的任意一种或多种,最优选乙酸以及乙酸与其它溶剂的混合体系,即乙酸与四氢呋喃、甲苯、苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺和N-甲基吡咯烷酮中的任意一种或多种的混合体系。In the preparation method of the compound of formula II of the present invention, in step Sa, it is preferably heated to 100°C-120°C; it is preferably cooled to room temperature after reacting for 2-4 hours; the organic solvent is preferably selected from acetic acid, tetrahydrofuran, toluene, Any one or more of benzene, N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone, most preferably acetic acid and the mixed system of acetic acid and other solvents, namely acetic acid Mixed system with any one or more of tetrahydrofuran, toluene, benzene, N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone.
进一步地,在步骤Sa与步骤Sb之间还可包括步骤Sc:对Sa步骤得到的进一步提纯,可采用重结晶和柱层析法,其中重结晶溶剂优选四氢呋喃、乙醇、甲苯或N,N-二甲基甲酰胺,更优选N,N-二甲基甲酰胺。Further, step Sc may also be included between step Sa and step Sb: for the step Sa obtained For further purification, recrystallization and column chromatography can be used, wherein the recrystallization solvent is preferably tetrahydrofuran, ethanol, toluene or N,N-dimethylformamide, more preferably N,N-dimethylformamide.
上述式I和式II的化合物均分别用于制备荧光探针的用途,特别是用于制备生物荧光探针的用途。The above-mentioned compounds of formula I and formula II are respectively used for the preparation of fluorescent probes, especially for the preparation of biological fluorescent probes.
实施本发明的式I和式II的化合物及其制备方法和应用,具有以下有益效果:本发明的式I和式II的化合物通过在Ar处(C2取代基位置)引入不同的取代基结构,实现对上述化合物的发光颜色、效率的调节;重点通过引入三苯基乙烯或四苯基乙烯基元及其衍生物结构,有效的遏制化合物在固态下效率的损失,实现其水系条件下高的荧光量子产率;通过选择不同的氨基羧酸结构作为反应物,在N1苯环处引入不同的羧酸结构,并通过适当的方法制备各种羧酸衍生结构,如酰卤、芳酸烷基酯、芳酸芳基酯、芳酸烷基酰胺或芳酸芳基酰胺等,以提高上述化合物结构的分子相容性、识别能力等;重点强调通过简单的卤化反应得到了一类水系稳定的酰氯结构,并通过晶体结构证明分子内电荷分离可能是稳定此类结构的关键因素;式I和式II化合物作为一类新型的探针结构,菲并咪唑羧酸和羧酸衍生物能够自由的进出细胞,并对特定结构进行选择性识别与成像,使其在生物、 医疗、健康和监测领域,具有极其广阔的应用前景。Implement the compound of formula I of the present invention and formula II and its preparation method and application, have following beneficial effect: the compound of formula I of the present invention and formula II is by introducing different substituent structures at Ar place (C2 substituent position), Realize the adjustment of the luminescent color and efficiency of the above compounds; focus on the introduction of triphenylethylene or tetraphenylethylene units and their derivative structures to effectively curb the loss of the efficiency of the compound in the solid state and achieve high efficiency under water system conditions. Fluorescence quantum yield; by selecting different aminocarboxylic acid structures as reactants, introducing different carboxylic acid structures at the N1 benzene ring, and preparing various carboxylic acid derivative structures by appropriate methods, such as acyl halides, aromatic acid alkyls Esters, aryl aryl esters, alkyl aryl amide or aryl aryl amide, etc., to improve the molecular compatibility and recognition ability of the above compound structures; emphasizing that a class of water stable Acyl chloride structure, and proved by crystal structure that intramolecular charge separation may be the key factor to stabilize this type of structure; Formula I and Formula II compounds are a new type of probe structure, phenanthroimidazole carboxylic acid and carboxylic acid derivatives can freely In and out of cells, and selective recognition and imaging of specific structures, it has extremely broad application prospects in the fields of biology, medicine, health and monitoring.
附图说明Description of drawings
图1A为TPE-PA在四氢呋喃与水的不同比例下的荧光光谱相对荧光强度变化曲线图;Fig. 1A is a graph showing the relative fluorescence intensity change curve of the fluorescence spectrum of TPE-PA under different ratios of tetrahydrofuran and water;
图1B为TPE-PAC在四氢呋喃与水的不同比例下的荧光光谱相对荧光强度变化曲线图;Figure 1B is a graph showing the relative fluorescence intensity change curve of the fluorescence spectrum of TPE-PAC under different ratios of tetrahydrofuran and water;
图2为TPE-PAC在水中pH值随时间变化的曲线图;Fig. 2 is a curve diagram of the pH value of TPE-PAC in water as a function of time;
图3A为TPE-PAC染色的Hela细胞在荧光显微镜下的明场照片;Figure 3A is a bright field photograph of TPE-PAC stained Hela cells under a fluorescence microscope;
图3B为TPE-PAC染色的Hela细胞在荧光显微镜下的荧光照片;Figure 3B is a fluorescent photo of TPE-PAC stained Hela cells under a fluorescent microscope;
图4为TPE-P2A在四氢呋喃与水的不同比例下的荧光光谱变化曲线图;Fig. 4 is a graph showing the change in fluorescence spectrum of TPE-P2A under different ratios of tetrahydrofuran and water;
图5A为TPE-P2A染色的Hela细胞在荧光显微镜下的明场照片;Figure 5A is a bright field photograph of TPE-P2A stained Hela cells under a fluorescence microscope;
图5B为TPE-P2A染色的Hela细胞在荧光显微镜下的荧光照片。Fig. 5B is a fluorescent photo of Hela cells stained with TPE-P2A under a fluorescent microscope.
具体实施方式Detailed ways
下面结合附图和实施例,对本发明的化合物I和化合物II及其制备方法和应用作进一步说明:Below in conjunction with accompanying drawing and embodiment, compound I and compound II of the present invention and preparation method thereof and application are further described:
本发明提供的一类可以作为新型荧光探针材料的式I和式II的化合物,即化合物I和化合物II,该材料为菲并咪唑羧酸及羧酸衍生物结构,其结构具有以下结构通式:A class of compounds provided by the present invention can be used as the compound of formula I and formula II of novel fluorescent probe material, i.e. compound I and compound II, this material is phenanthroimidazole carboxylic acid and carboxylic acid derivative structure, and its structure has following general structure Mode:
上述结构以9,10-菲并咪唑为核心结构,Ar表示芳香基团或其衍生结构,分别选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、三苯基乙烯、四苯基乙烯等及相应的衍生结构中的一种。R和R1分别表示在咪唑中N1取代苯环上的任意取代位置的羰基链接取代基结构,分别选自羟基、卤素、烷氧基或芳香酚基团、胺基及芳香胺基等构筑的羧酸基团衍生结构。G1和G2表示菲环上任意位置的任意取代基团。The above structure takes 9,10-phenanthroimidazole as the core structure, and Ar represents an aromatic group or its derivative structure, which are respectively selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyran One of base, quinolinyl, indolyl, carbazolyl, anilino, triphenylethylene, tetraphenylethylene, etc. and the corresponding derivative structures. R and R1 respectively represent the carbonyl link substituent structure of any substitution position on the N1 substituted benzene ring in imidazole, which are respectively selected from hydroxyl, halogen, alkoxy or aromatic phenol groups, amino groups and aromatic amino groups. Carboxylic acid group derivative structure. G1 and G2 represent any substituent groups at any position on the phenanthrene ring.
具体合成过程:Specific synthesis process:
(1)(1)
通过各种耦联、取代和缩合等反应得到芳香醛和菲醌的衍生物结构。芳香醛和菲醌的衍生物均为现有化合物,其合成过程为现有技术,这里不再赘述具体制备过程。The derivative structures of aromatic aldehydes and phenanthrenequinones were obtained through various coupling, substitution and condensation reactions. The derivatives of aromatic aldehydes and phenanthrenequinones are all existing compounds, and their synthesis process is prior art, and the specific preparation process will not be repeated here.
(2)(2)
将上述芳香醛衍生物、菲醌衍生物、乙酸铵和氨基苯甲酸(或氨基苯二甲酸)采用“一锅法”在适当的溶剂和温度制备重要的羧酸结构。The above-mentioned aromatic aldehyde derivatives, phenanthrenequinone derivatives, ammonium acetate and aminobenzoic acid (or aminophthalic acid) were prepared in a "one-pot method" in an appropriate solvent and temperature to prepare important carboxylic acid structures.
具体操作:将芳香醛衍生物、菲醌衍生物、乙酸铵和氨基苯甲酸(或氨基苯二甲酸)在有机溶剂中加热至适当温度,反应一段时间后冷却至室温,过滤得到羧酸结构(进一步提纯采用重结晶和柱层析法)。其中,有机溶剂优选乙酸、四氢呋喃、甲苯、苯、N,N-二甲基甲酰胺(DMF),N,N-二甲基乙酰胺(DMAC)和N-甲基吡咯烷酮(NMP)等或二者、三者的混合体系,最优选乙酸及其与其他溶剂的混合体系;温度优选80℃至180℃,其中最优选为100℃至120℃;反应时间优选1小时至24小时,其中最优选2小时至4小时;重结晶溶剂,优选四氢呋喃、乙醇、甲苯、DMF等,最优选DMF。Concrete operation: heating aromatic aldehyde derivatives, phenanthrenequinone derivatives, ammonium acetate and aminobenzoic acid (or aminophthalic acid) to an appropriate temperature in an organic solvent, cooling to room temperature after a period of reaction, and filtering to obtain a carboxylic acid structure ( Further purification using recrystallization and column chromatography). Among them, the organic solvent is preferably acetic acid, tetrahydrofuran, toluene, benzene, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP), etc. or two or a mixed system of the three, most preferably acetic acid and its mixed system with other solvents; the temperature is preferably 80°C to 180°C, and the most preferred is 100°C to 120°C; the reaction time is preferably 1 hour to 24 hours, and the most preferred 2 hours to 4 hours; recrystallization solvent, preferably tetrahydrofuran, ethanol, toluene, DMF, etc., most preferably DMF.
(3)(3)
将上述羧酸结构采用对应方法,分别得到菲并咪唑N1苯环的取代的酰卤、芳酸烷基酯、芳酸芳基酯、芳酸烷基酰胺或芳酸芳基酰胺等。需要说明的是,其具体的取代反应过程均为现有技术,这里不再进行详细赘述。The above-mentioned carboxylic acid structure adopts the corresponding method to obtain the substituted acyl halide, alkyl arylate, aryl aryl ester, alkyl aryl amide or aryl aryl amide of phenanthroimidazole N1 benzene ring respectively. It should be noted that the specific substitution reaction processes are all prior art, and will not be described in detail here.
进一步地,G1和G2分别表示氢。Further, G1 and G2 respectively represent hydrogen.
进一步地,Ar为任意芳基结构,取代基R和R1为羟基、卤素、烷氧基或芳香酚基团、胺基及芳香胺基及其衍生物时,其优选化合物结构为:Further, when Ar is any aryl structure, substituent R and R 1 are hydroxyl, halogen, alkoxyl group or aromatic phenol group, amine group and aromatic amine group and derivatives thereof, its preferred compound structure is:
其中,X为F、Cl、Br和I中的一种,R2-R5各自分别为氢、烷基、羟基、烷氧基、硝基、氰基、氨基、巯基、卤素原子等(进一步地,其中烷基或烷氧基的碳原子数为1~12),Ar’和Ar”各自分别选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、三苯基乙烯、四苯基乙烯等及相应的衍生结构中的一种。Wherein, X is a kind of in F, Cl, Br and I, and R 2 -R 5 are respectively hydrogen, alkyl, hydroxyl, alkoxy, nitro, cyano, amino, mercapto, halogen atom etc. (further wherein the number of carbon atoms in the alkyl or alkoxy group is 1 to 12), Ar' and Ar" are each selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyridyl One of pyryl, quinolinyl, indolyl, carbazolyl, anilino, triphenylethylene, tetraphenylethylene, etc. and the corresponding derivative structures.
进一步地,Ar被限制为苯环或苯环衍生物、萘环或萘环衍生物、蒽环或蒽环衍生物取代基,其化合物通式及优选化合物结构如下,且用表示N1苯环上由羟基、卤素、烷氧基或芳香酚基团、胺基及芳香胺基等所构筑的羧酸基团衍生结构:Further, Ar is limited to a benzene ring or a benzene ring derivative, a naphthalene ring or a naphthalene ring derivative, an anthracycline or an anthracycline derivative substituent, and its compound general formula and preferred compound structure are as follows, and use Represents the derivative structure of carboxylic acid groups constructed by hydroxyl, halogen, alkoxy or aromatic phenol groups, amine groups and aromatic amine groups on the N1 benzene ring:
其中,A1-A9各自分别为氢、烷基、羟基、烷氧基、硝基、氰基、氨基、巯基、卤素原子、苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、羧酸或羧酸衍生物、咔唑基或苯胺基及相应的衍生结构中的一种(进一步地,其中烷基或烷氧基的碳原子数为1~12)。Wherein, A 1 -A 9 are each hydrogen, alkyl, hydroxyl, alkoxy, nitro, cyano, amino, mercapto, halogen atom, phenyl, tolyl, naphthyl, furyl, thienyl, pyrrole One of base, pyridyl, pyranyl, quinolinyl, indolyl, carboxylic acid or carboxylic acid derivatives, carbazolyl or anilino and corresponding derivative structures (further, wherein alkyl or alkoxy The number of carbon atoms in the group is 1 to 12).
进一步地,Ar被限制为三苯基乙烯及三苯基乙烯衍生物,其化合物通式及优选化合物结构如下,且用表示N1苯环上由羟基、卤素、烷氧基或芳香酚基团、胺基及芳香胺基等所构筑的羧酸基团衍生结构:Further, Ar is limited to triphenylethylene and triphenylethylene derivatives, its general formula and preferred compound structure are as follows, and use Represents the derivative structure of carboxylic acid groups constructed by hydroxyl, halogen, alkoxy or aromatic phenol groups, amine groups and aromatic amine groups on the N1 benzene ring:
其中,Ar”’选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、苯并噻二唑及相应的衍生结构或者是任意二者组成的新的芳香基团的一种;B1-B15各自分别为氢、烷基、羟基、烷氧基、硝基、氰基、氨基、巯基、卤素原子、苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、羧酸或羧酸衍生物、咔唑基或苯胺基中的一种或相应衍生物等中的一种(进一步地,其中烷基或烷氧基的碳原子数为1~12)。Among them, Ar"' is selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carbazolyl, anilino, benzothio Oxadiazole and the corresponding derivative structure or one of the new aromatic groups composed of any two; B 1 -B 15 are each hydrogen, alkyl, hydroxyl, alkoxy, nitro, cyano, amino, Mercapto, halogen atom, phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carboxylic acid or carboxylic acid derivatives, carbazolyl or One of the anilino groups or one of the corresponding derivatives (further, the number of carbon atoms in the alkyl or alkoxy group is 1 to 12).
进一步地,Ar被限制为四苯基乙烯及四苯基乙烯衍生物,其化合物通式及优选化合物结构如下,且用表示N1苯环上由羟基、卤素、烷氧基或芳香酚基团、胺基及芳香胺基等所构筑的羧酸基团衍生结构:Further, Ar is limited to tetraphenylethylene and tetraphenylethylene derivatives, its general formula and preferred compound structure are as follows, and use Represents the derivative structure of carboxylic acid groups constructed by hydroxyl, halogen, alkoxy or aromatic phenol groups, amine groups and aromatic amine groups on the N1 benzene ring:
其中,Ar”’选自苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、咔唑基、苯胺基、苯并噻二唑及相应的衍生结构或者是任意二者组成的新的芳香基团的一种;B1-B15各自分别为氢、烷基、羟基、烷氧基、硝基、氰基、氨基、巯基、卤素原子、苯基、甲苯基、萘基、呋喃基、噻吩基、吡咯基、吡啶基、吡喃基、喹啉基、吲哚基、羧酸或羧酸衍生物、咔唑基或苯胺基中的一种或相应衍生物等中的一种(进一步地,其中烷基或烷氧基的碳原子数为1~12)。Among them, Ar"' is selected from phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carbazolyl, anilino, benzothio Oxadiazole and the corresponding derivative structure or one of the new aromatic groups composed of any two; B 1 -B 15 are each hydrogen, alkyl, hydroxyl, alkoxy, nitro, cyano, amino, Mercapto, halogen atom, phenyl, tolyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyranyl, quinolinyl, indolyl, carboxylic acid or carboxylic acid derivatives, carbazolyl or One of the anilino groups or one of the corresponding derivatives (further, the number of carbon atoms in the alkyl or alkoxy group is 1 to 12).
进一步地,Ar为呋喃、噻吩、吡咯、吡啶、吡喃、喹啉(含异喹啉)、吲哚、咔唑、苯胺基、苯并噻二唑及其相应的衍生结构,或者是任意二者组成的新的芳香基团的一种,其化合物通式及优选化合物结构如下,且用表示N1苯环上由羟基、卤素、烷氧基或芳香酚基团、胺基及芳香胺基等所构筑的羧酸基团衍生结构:Further, Ar is furan, thiophene, pyrrole, pyridine, pyran, quinoline (containing isoquinoline), indole, carbazole, anilino, benzothiadiazole and their corresponding derivative structures, or any two One of the new aromatic groups composed of those whose compound general formula and preferred compound structure are as follows, and use Represents the derivative structure of carboxylic acid groups constructed by hydroxyl, halogen, alkoxy or aromatic phenol groups, amine groups and aromatic amine groups on the N1 benzene ring:
上述所有结构式中,其中芳基和烷基优选结构可以选自下式中所示29种中的一种或氢原子:In all above-mentioned structural formulas, wherein the preferred structure of aryl and alkyl can be selected from one of the 29 shown in the following formula or a hydrogen atom:
实施例1:苯基-菲并咪唑-N1-羧酸及衍生物的合成Embodiment 1: the synthesis of phenyl-phenanthroimidazole-N1-carboxylic acid and derivatives
将适量苯甲醛、菲醌、对氨基苯甲酸和过量的乙酸铵在冰醋酸中120℃反应3小时后冷却至室温,过滤得到羧酸衍生物。将其溶解于N,N-二甲基甲酰胺和二氯亚砜的混合溶剂中,80℃反应4小时后旋走未反应的二氯亚砜。加入过量的苯胺回流4小时,色谱柱分离得到目标化合物结构。1H NMR(DMSO,500MHz):δ:10.6(s,1H),8.96(d,1H),8.90(d,1H),8.70(d,1H),8.21(d,2H),7.85(d,2H),7.79(t,1H),7.71(t,1H),7.60-7.56(m,5H),7.40-7.37(m,7H),7.11(d,1H).MALDI-TOF(m/z):[M+]calcd.C34H23N3O,489.5659;found,490.59.React an appropriate amount of benzaldehyde, phenanthrenequinone, p-aminobenzoic acid and excess ammonium acetate in glacial acetic acid at 120°C for 3 hours, cool to room temperature, and filter to obtain a carboxylic acid derivative. Dissolve it in a mixed solvent of N,N-dimethylformamide and thionyl chloride, react at 80°C for 4 hours, and then spin off unreacted thionyl chloride. Excessive aniline was added to reflux for 4 hours, and the structure of the target compound was obtained through chromatographic column separation. 1 H NMR(DMSO,500MHz):δ:10.6(s,1H),8.96(d,1H),8.90(d,1H),8.70(d,1H),8.21(d,2H),7.85(d, 2H),7.79(t,1H),7.71(t,1H),7.60-7.56(m,5H),7.40-7.37(m,7H),7.11(d,1H).MALDI-TOF(m/z) :[M+]calcd.C 34 H 23 N 3 O, 489.5659; found, 490.59.
实施例2:1-萘基-菲并咪唑-N1-羧酸及衍生物的合成Embodiment 2: Synthesis of 1-naphthyl-phenanthroimidazole-N1-carboxylic acid and derivatives
将适量1-萘甲醛、菲醌、对氨基苯甲酸和过量的乙酸铵在冰醋酸中120℃反应3小时后冷却至室温,过滤得到羧酸衍生物。将其溶解于N,N-二甲基甲酰胺和二氯亚砜的混合溶剂中,80℃反应4小时后旋走未反应的二氯亚砜。加入过量的苯胺回流4小时,色谱柱分离得到目标化合物结构。1H NMR(500MHz,DMSO-d6)δ13.27(s,1H),9.02-8.97(m,1H),8.94(d,J=8.3Hz,1H),8.67(dd,J=7.9,1.4Hz,1H), 8.02-7.93(m,4H),7.91(dd,J=8.2,1.4Hz,1H),7.83-7.65(m,5H),7.61(ddd,J=8.4,7.0,1.4Hz,1H),7.60-7.45(m,3H),7.41(ddd,J=8.1,6.9,1.1Hz,1H),7.14(dd,J=8.3,1.2Hz,1H).MALDI-TOF(m/z):[M+]calcd.C38H25N3O,539.6246;found,540.77.React an appropriate amount of 1-naphthaldehyde, phenanthrenequinone, p-aminobenzoic acid and excess ammonium acetate in glacial acetic acid at 120°C for 3 hours, cool to room temperature, and filter to obtain a carboxylic acid derivative. Dissolve it in a mixed solvent of N,N-dimethylformamide and thionyl chloride, react at 80°C for 4 hours, and then spin off unreacted thionyl chloride. Excessive aniline was added to reflux for 4 hours, and the structure of the target compound was obtained through chromatographic column separation. 1 H NMR (500MHz, DMSO-d 6 ) δ13.27(s, 1H), 9.02-8.97(m, 1H), 8.94(d, J=8.3Hz, 1H), 8.67(dd, J=7.9, 1.4 Hz,1H), 8.02-7.93(m,4H),7.91(dd,J=8.2,1.4Hz,1H),7.83-7.65(m,5H),7.61(ddd,J=8.4,7.0,1.4Hz, 1H),7.60-7.45(m,3H),7.41(ddd,J=8.1,6.9,1.1Hz,1H),7.14(dd,J=8.3,1.2Hz,1H).MALDI-TOF(m/z) : [M+]calcd.C 38 H 25 N 3 O, 539.6246; found, 540.77.
实施例3:2-萘基-菲并咪唑-N1-羧酸及衍生物的合成Embodiment 3: Synthesis of 2-naphthyl-phenanthroimidazole-N1-carboxylic acid and derivatives
将适量2-萘甲醛、菲醌、对氨基苯甲酸和过量的乙酸铵在冰醋酸中120℃反应3小时后冷却至室温,过滤得到羧酸衍生物。将其溶解于N,N-二甲基甲酰胺和二氯亚砜的混合溶剂中,80℃反应4小时后旋走未反应的二氯亚砜。加入过量的苯胺回流4小时,色谱柱分离得到目标化合物结构。1HNMR(500MHz,DMSO-d6)δ10.36(s,1H),8.98(dd,J=28.1,8.4Hz,2H),8.67(dd,J=8.0,1.4Hz,1H),8.04-7.90(m,5H),7.83-7.69(m,7H),7.66-7.49(m,4H),7.43(ddd,J=8.2,7.0,1.1Hz,1H),7.35(t,J=7.9Hz,2H),7.18(dd,J=8.4,1.2Hz,1H),7.11(dd,J=8.0,6.7Hz,1H).MALDI-TOF(m/z):[M+]calcd.C38H25N3O,539.6246;found,540.45.React an appropriate amount of 2-naphthaldehyde, phenanthrenequinone, p-aminobenzoic acid and excess ammonium acetate in glacial acetic acid at 120°C for 3 hours, cool to room temperature, and filter to obtain a carboxylic acid derivative. Dissolve it in a mixed solvent of N,N-dimethylformamide and thionyl chloride, react at 80°C for 4 hours, and then spin off unreacted thionyl chloride. Excess aniline was added to reflux for 4 hours, and the structure of the target compound was obtained through chromatographic column separation. 1 HNMR (500MHz, DMSO-d 6 )δ10.36(s, 1H), 8.98(dd, J=28.1, 8.4Hz, 2H), 8.67(dd, J=8.0, 1.4Hz, 1H), 8.04-7.90 (m,5H),7.83-7.69(m,7H),7.66-7.49(m,4H),7.43(ddd,J=8.2,7.0,1.1Hz,1H),7.35(t,J=7.9Hz,2H ), 7.18 (dd, J=8.4, 1.2Hz, 1H), 7.11 (dd, J=8.0, 6.7Hz, 1H). MALDI-TOF (m/z): [M+] calcd. C 38 H 25 N 3 O, 539.6246; found, 540.45.
实施例4:四苯基乙烯-菲并咪唑-N1-羧酸及衍生物的合成Embodiment 4: Synthesis of tetraphenylethylene-phenanthroimidazole-N1-carboxylic acid and derivatives
将适量四苯乙烯基甲醛、菲醌、对氨基苯甲酸和过量的乙酸铵在冰醋酸中120℃反应3小时后冷却至室温,过滤,柱层析得到羧酸衍生物TPE-PA。MALDI-TOF(m/z):[M+]calcd.C48H32N2O2,668.7799;found,668.8732.Anal Calc.for C48H32N2O2:C,86.20;H,4.82;N,4.19;O,4.78.Found:C,86.12;H,4.77;N,4.20;O,4.74.Appropriate amount of tetrastyryl formaldehyde, phenanthrenequinone, p-aminobenzoic acid and excess ammonium acetate were reacted in glacial acetic acid at 120°C for 3 hours, cooled to room temperature, filtered, and column chromatographed to obtain the carboxylic acid derivative TPE-PA. MALDI-TOF (m/z): [M+] calcd. C 48 H 32 N 2 O 2 , 668.7799; found, 668.8732. Anal Calc. for C 48 H 32 N 2 O 2 : C, 86.20; H, 4.82; N, 4.19; O, 4.78. Found: C, 86.12; H, 4.77; N, 4.20; O, 4.74.
将TPE-PA溶解于N,N-二甲基甲酰胺(少量)和二氯亚砜的混合溶剂中,80℃反应4小时后旋走未反应的二氯亚砜,用水和二氯甲烷萃取后干燥,色谱柱分离得到酰氯化合物结构TPE-PAC。MALDI-TOF(m/z):[M+]calcd.C48H31ClN2O,687.2255;found,687.2345.AnalCalc.for C48H31ClN2O:C,83.89;H,4.55;Cl,5.16;N,4.08;O,2.33Found:C,83.87;H,4.53;N,4.09;O,2.32。Dissolve TPE-PA in a mixed solvent of N,N-dimethylformamide (a small amount) and thionyl chloride, react at 80°C for 4 hours, spin off unreacted thionyl chloride, extract with water and dichloromethane After drying, chromatographic column separation to obtain the acid chloride compound structure TPE-PAC. MALDI-TOF (m/z): [M+]calcd. C 48 H 31 ClN 2 O, 687.2255; found, 687.2345. AnalCalc. for C 48 H 31 ClN 2 O: C, 83.89; H, 4.55; ; N, 4.08; O, 2.33 Found: C, 83.87; H, 4.53; N, 4.09; O, 2.32.
实施例5:TPE-PA和TPE-PAC的聚集诱导发光(AIE)性质研究Example 5: Research on Aggregation-Induced Emission (AIE) Properties of TPE-PA and TPE-PAC
如图1A和1B所示,分别为TPE-PA和TPE-PAC在四氢呋喃与水的不同比例下的荧光光谱相对荧光强度变化曲线,随着水含量的增加,二者的荧光强度明显增加,具有明显的聚集诱导发光现象,是一类潜在的荧光分子探针。As shown in Figures 1A and 1B, they are the relative fluorescence intensity curves of the fluorescence spectra of TPE-PA and TPE-PAC under different ratios of tetrahydrofuran and water. As the water content increases, the fluorescence intensity of the two increases significantly, with The obvious aggregation-induced luminescent phenomenon is a kind of potential fluorescent molecular probe.
实施例6:TPE-PAC水系稳定性研究Embodiment 6: Study on the stability of TPE-PAC water system
如图2所示,为TPE-PAC在水中pH值随时间变化曲线。通常条件下,酰氯在水中会快速水解为对应的羧酸和氯化氢,进而失去高 的反应活性,但是TPE-PAC由于咪唑的特殊性在水系条件可以表现出显著的稳定性。在搅拌条件下,1500分钟内通过pH值变化估计其分解率仅为25%,是一类水系下稳定的酰氯结构。而且,该酰氯结构可以正常的进行萃取和柱层析,表明其可以作为水系条件下的荧光分子探针基元。As shown in Figure 2, it is the curve of the pH value of TPE-PAC in water versus time. Under normal conditions, acid chlorides will be rapidly hydrolyzed into corresponding carboxylic acids and hydrogen chloride in water, thereby losing high reactivity, but TPE-PAC can show remarkable stability in water system conditions due to the particularity of imidazole. Under the condition of stirring, its decomposition rate is estimated to be only 25% according to the change of pH value within 1500 minutes, and it is a kind of stable acid chloride structure in water system. Moreover, the acid chloride structure can be normally subjected to extraction and column chromatography, indicating that it can be used as a fluorescent molecular probe motif under aqueous conditions.
实施例7:TPE-PAC细胞染色实验Embodiment 7: TPE-PAC cell staining experiment
将TPE-PAC配成一定浓度的DMSO溶液后,滴入细胞培养液中,选择Hela细胞作为研究对象,培养一段时间后采用荧光显微镜对其极性观察,如图3A和3B所示,发现TPE-PAC可以顺利的透过细胞壁,并定向的在细胞质处富集,从而显示出蓝色荧光,说明该类酰氯结构在水系条件下可以作为荧光探针使用。After making TPE-PAC into a certain concentration of DMSO solution, drop it into the cell culture medium, select Hela cells as the research object, and observe its polarity with a fluorescence microscope after culturing for a period of time, as shown in Figure 3A and 3B, it was found that TPE -PAC can pass through the cell wall smoothly, and is enriched in the cytoplasm in a directional manner, thereby showing blue fluorescence, indicating that this type of acid chloride structure can be used as a fluorescent probe under aqueous conditions.
实施例8:四苯基乙烯-菲并咪唑-N1-羧酸衍生物TPE-P2A的合成Example 8: Synthesis of tetraphenylethylene-phenanthroimidazole-N1-carboxylic acid derivative TPE-P2A
将适量四苯乙烯基甲醛、菲醌、对氨基苯二酸和过量的乙酸铵在冰醋酸中120℃反应3小时后冷却至室温,过滤,柱层析得到羧酸衍生物TPE-P2A。MALDI-TOF(m/z):[M+]calcd.C49H32N2O4,712.7894;found,712.7902.Anal Calc.for C49H32N2O4:C,82.57;H,4.53;N,3.93;O,8.98.Found:C,82.48;H,4.45;N,3.9387;O,8.68.Appropriate amount of tetrastyryl formaldehyde, phenanthrenequinone, p-aminophthalic acid and excess ammonium acetate were reacted in glacial acetic acid at 120°C for 3 hours, cooled to room temperature, filtered, and column chromatographed to obtain the carboxylic acid derivative TPE-P2A. MALDI-TOF (m/z): [M+] calcd. C 49 H 32 N 2 O 4 , 712.7894; found, 712.7902. Anal Calc. for C 49 H 32 N 2 O 4 : C, 82.57; H, 4.53; N, 3.93; O, 8.98. Found: C, 82.48; H, 4.45; N, 3.9387; O, 8.68.
实施例9:TPE-P2A的聚集诱导发光(AIE)性质研究Example 9: Research on Aggregation-Induced Emission (AIE) Properties of TPE-P2A
如图4所示,为TPE-P2A在四氢呋喃与水的不同比例下的荧光光谱变化曲线,随着水含量的增加,二者的荧光强度明显增加,具有明显的聚集诱导发光现象,可以作为一类荧光分子探针。As shown in Figure 4, it is the fluorescence spectrum change curve of TPE-P2A under different ratios of tetrahydrofuran and water. As the water content increases, the fluorescence intensity of the two increases significantly, and there is obvious aggregation-induced luminescence phenomenon, which can be used as a Fluorescent molecular probes.
实施例10:TPE-P2A细胞染色实验Embodiment 10: TPE-P2A cell staining experiment
将TPE-P2A配成一定浓度溶液DMSO溶液后,滴入细胞培养液中,选择Hela细胞作为研究对象,培养一段时间后采用荧光显微镜对其极性观察,如图5A和5B所示,发现TPE-P2A可以顺利的透过细胞壁,并定向的在细胞质处富集,从而显示出蓝色荧光,说明该类二羧酸结构具有自活化性能,可以作为荧光探针使用。After making TPE-P2A into a certain concentration of DMSO solution, drop it into the cell culture medium, select Hela cells as the research object, and observe its polarity with a fluorescence microscope after culturing for a period of time, as shown in Figures 5A and 5B, it was found that TPE -P2A can pass through the cell wall smoothly and be enriched in the cytoplasm in a directional manner, thereby showing blue fluorescence, indicating that the dicarboxylic acid structure has self-activation properties and can be used as a fluorescent probe.
应当理解的是,对本领域普通技术人员来说,可以根据上述说明加以改进或变换,所有这些改进或变换都应属于本发明所附权利要求的保护范围之内。It should be understood that those skilled in the art can make improvements or changes based on the above description, and all these improvements or changes should fall within the protection scope of the appended claims of the present invention.
Claims (8)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510730596.5A CN106632063B (en) | 2015-10-30 | 2015-10-30 | Compound I and compound II based on phenanthroimidazole and its preparation method and application |
PCT/CN2016/097319 WO2017071398A1 (en) | 2015-10-30 | 2016-08-30 | Compound i and compound ii, preparation method for both, and applications thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510730596.5A CN106632063B (en) | 2015-10-30 | 2015-10-30 | Compound I and compound II based on phenanthroimidazole and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106632063A CN106632063A (en) | 2017-05-10 |
CN106632063B true CN106632063B (en) | 2019-10-22 |
Family
ID=58631274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510730596.5A Active CN106632063B (en) | 2015-10-30 | 2015-10-30 | Compound I and compound II based on phenanthroimidazole and its preparation method and application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN106632063B (en) |
WO (1) | WO2017071398A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108191847B (en) * | 2018-01-08 | 2021-01-05 | 吉林大学 | Asymmetric donor-acceptor type organic red fluorescent small molecular material and application thereof in organic electroluminescent device |
CN113265057A (en) * | 2020-02-14 | 2021-08-17 | 台州学院 | Covalent-organic framework material and preparation method thereof |
CN111440201B (en) * | 2020-04-30 | 2022-06-21 | 齐齐哈尔大学 | Preparation method and application of organic compound |
CN112679732B (en) * | 2020-12-28 | 2021-10-26 | 华南理工大学 | Luminescent polymer and metal-free catalyst polymerization method and application thereof |
CN113512049A (en) * | 2021-03-26 | 2021-10-19 | 广州万物物联科技有限公司 | Phenanthroimidazole-based blue light bipolar small molecule and preparation method thereof |
CN116283787A (en) * | 2023-03-24 | 2023-06-23 | 绍兴文理学院 | Phenanthroimidazole fluorescent amine compound labeling reagent and synthesis method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103539749A (en) * | 2013-10-12 | 2014-01-29 | Tcl集团股份有限公司 | Phenanthrene quinoxaline fluorescent compound and preparation method and application thereof, and electroluminescent device |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101460365B1 (en) * | 2008-04-29 | 2014-11-10 | 주식회사 엘지화학 | Novel imidazole derivatives and organic electronic devices using the same |
CN103755702B (en) * | 2014-01-29 | 2016-02-24 | 清华大学 | Phenanthro-imidazo isoquinoline 99.9 and derivative and preparation method thereof thereof and application |
CN104030988B (en) * | 2014-06-25 | 2016-07-06 | 上海道亦化工科技有限公司 | A kind of electron transport compound based on benzimidazole |
-
2015
- 2015-10-30 CN CN201510730596.5A patent/CN106632063B/en active Active
-
2016
- 2016-08-30 WO PCT/CN2016/097319 patent/WO2017071398A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103539749A (en) * | 2013-10-12 | 2014-01-29 | Tcl集团股份有限公司 | Phenanthrene quinoxaline fluorescent compound and preparation method and application thereof, and electroluminescent device |
Non-Patent Citations (3)
Title |
---|
N1取代基结构对菲并咪唑荧光色纯度的影响;王志明等;《高等学校化学学报》;20141231;第35卷(第3期);第505-510页 * |
Photochemical Conversion of Phenanthro[9,10-d]imidazoles into π-Expanded Heterocycles;Kamil Skonieczny,et al.;《The Journal of Organic Chemistry》;20150504;第80卷;第5753-5763页 * |
RN1680185-58-3,RN1777807-14-3;Registry;《STN Columbus》;20150610 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017071398A1 (en) | 2017-05-04 |
CN106632063A (en) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106632063B (en) | Compound I and compound II based on phenanthroimidazole and its preparation method and application | |
CN105541660B (en) | A kind of aryl salicylide diphenyl azine connection hydrazine class compound and preparation and application | |
CN108440475B (en) | Ratio type fluorescent probe for distinguishing lipid droplets with different polarities and preparation method and application thereof | |
CN110234735B (en) | Bimodal biological imaging probe | |
CN106478458B (en) | Schiff base compound and its preparation method and application based on tetraphenylethylene and Maleic nitrile | |
CN107098923A (en) | One class feux rouges targets fluorescent dye and preparation method thereof and purposes near infrared emission lysosome | |
CN108864056B (en) | Near infrared fluorescent compound and its preparation method and application with AIE performance | |
CN107226783B (en) | A kind of lysosome targeting fluorescent probe and preparation method thereof | |
CN104357045A (en) | Synthesis method of spiropyrane small-molecule fluorescent probe with extreme acid/extreme alkaline switch response and application of spiropyrane small-molecule fluorescent probe | |
CN114773875B (en) | Azaindole-squaraine dye, and synthetic method and application thereof | |
CN103773060B (en) | Organic fluorescent dye molecule and synthetic method thereof and application | |
CN106867271A (en) | The naphthalimide fluorescent dyestuff and its synthetic method and application of a kind of big Stokes shift and launch wavelength long | |
CN109503550B (en) | 2-azaaryl-6-substituted aminoquinazolone compound and its preparation method and application | |
CN112851556B (en) | Novel aggregation-induced emission Golgi fluorescence probe and preparation method and application thereof | |
CN112250700B (en) | Halo-BODIPY, a probe for misfolding of fluoroborodipyrrole proteins and its preparation method and application | |
CN104327537A (en) | Xanthene fluorescent dye with biofilm permeability potential and preparation method thereof | |
CN106146342A (en) | Fluorenyl salicylide buzane analog derivative and its preparation method and application | |
CN111892588A (en) | A kind of indole-benzothiazole derivative and its preparation method and application | |
CN114702447B (en) | Naphthalimide derivative and preparation method and application thereof | |
CN114133413B (en) | Benzothiazole-triphenylamine compound and preparation method and application thereof | |
CN111334070A (en) | 532nm excited rhodamine fluorescent dye and preparation method thereof | |
CN112940714B (en) | Wash-free Halo-tag probe with high fluorescence quantum yield and synthetic method and application thereof | |
CN112939936B (en) | Carbonyl azetidine substituted naphthalimide fluorescent dye and synthetic method and application thereof | |
CN111333574B (en) | Carbonic anhydrase detection fluorescent probe with high brightness and high light stability | |
CN110407764B (en) | Chiral fluorescent compound based on cyclophane alkyl skeleton and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |